PHAT Phathom Pharmaceuticals, Inc. Stock Quote

PHAT [NASD]

Index	-	P/E	-	EPS (ttm)	-6.81	Insider Own	17.16%	Shs Outstand	25.92M	Perf Week	4.18%
Market Cap	1.50B	Forward P/E	-	EPS next Y	-3.76	Insider Trans	-4.97%	Shs Float	9.71M	Perf Month	7.27%
Income	-173.40M	PEG	-	EPS next Q	-1.01	Inst Own	79.50%	Short Float	4.87%	Perf Quarter	2.55%
Sales	-	P/S	-	EPS this Y	84.80%	Inst Trans	12.36%	Short Ratio	3.13	Perf Half Y	30.37%
Book/sh	6.03	P/B	7.61	EPS next Y	-10.30%	ROA	-69.00%	Target Price	54.50	Perf Year	9.81%
Cash/sh	6.94	P/C	6.61	EPS next 5Y	-	ROE	-88.70%	52W Range	22.06 - 64.54	Perf YTD	38.14%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-28.90%	Beta	-
Dividend %	-	Quick Ratio	8.20	Sales past 5Y	-	Gross Margin	-	52W Low	108.02%	ATR	2.79
Employees	25	Current Ratio	8.20	Sales Q/Q	-	Oper. Margin	-	RSI (14)	56.83	Volatility	8.22% 5.63%
Optionable	Yes	Debt/Eq	0.30	EPS Q/Q	52.60%	Profit Margin	-	Rel Volume	0.85	Prev Close	44.17
Shortable	Yes	LT Debt/Eq	0.26	Earnings	-	Payout	-	Avg Volume	150.79K	Price	45.89
Recom	2.00	SMA20	2.27%	SMA50	13.94%	SMA200	17.12%	Volume	128,553	Change	3.89%

Feb-17-21

Initiated

BMO Capital Markets

Outperform

$63

Feb-02-21

Initiated

Guggenheim

Buy

$60

Jun-26-20

Downgrade

Goldman

Neutral → Sell

$34

Nov-20-19

Initiated

Evercore ISI

Outperform

Nov-19-19

Initiated

Needham

Buy

$40

Nov-19-19

Initiated

Jefferies

Buy

$32

Nov-19-19

Initiated

Goldman

Neutral

$32

Feb-17-21 10:12AM	Benzinga's Top Ratings Upgrades, Downgrades For February 17, 2021 Benzinga
Feb-02-21 10:07AM	Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2021 Benzinga +11.07%
Jan-19-21 08:30AM	Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial GlobeNewswire
Dec-16-20 06:43PM	Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire -8.40%
Dec-15-20 04:01PM	Phathom Pharmaceuticals Announces Proposed Public Offering of 2,250,000 Shares of Common Stock GlobeNewswire +13.05%
Dec-14-20 08:30AM	Phathom Pharmaceuticals Announces Plans to Initiate Vonoprazan Development Program in Non-Erosive Reflux Disease (NERD) GlobeNewswire
Dec-08-20 09:00AM	Phathom Pharmaceuticals (PHAT) Surges: Stock Moves 6.9% Higher Zacks
Dec-02-20 11:33PM	Here is What Hedge Funds Think About Phathom Pharmaceuticals, Inc. (PHAT) Insider Monkey
Nov-30-20 04:05PM	Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Erosive Esophagitis Trial GlobeNewswire
Nov-27-20 08:00AM	Phathom Pharmaceuticals to Participate at Upcoming Investor Healthcare Conferences GlobeNewswire
Nov-19-20 04:05PM	Phathom Pharmaceuticals to Host Virtual Investor Day GlobeNewswire
Nov-13-20 04:05PM	Phathom Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference GlobeNewswire +5.63%
Nov-10-20 04:05PM	Phathom Pharmaceuticals Reports Third Quarter 2020 Results and Provides Update on Phase 3 Trials GlobeNewswire
Nov-04-20 04:05PM	Arcutis Announces Appointment of Terrie Curran to Board of Directors GlobeNewswire
Sep-09-20 08:30AM	Phathom Pharmaceuticals to Present at Morgan Stanley 18th Annual Global Healthcare Conference GlobeNewswire +7.00%
Aug-06-20 08:30AM	Phathom Pharmaceuticals Reports Second Quarter 2020 Results GlobeNewswire
Jul-13-20 08:30AM	Phathom Pharmaceuticals Announces Appointment of Todd Branning as Chief Financial Officer GlobeNewswire
Jun-15-20 08:30AM	Phathom Pharmaceuticals Provides Clinical Trial Status Update GlobeNewswire -12.74%
Jun-12-20 10:25PM	Hedge Funds Are Selling Phathom Pharmaceuticals, Inc. (PHAT) Insider Monkey
May-28-20 04:30PM	Phathom Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire -6.72%
May-12-20 08:30AM	Phathom Pharmaceuticals Reports First Quarter 2020 Results GlobeNewswire
Apr-09-20 04:30PM	Phathom to Participate at the 19th Annual Needham Virtual Healthcare Conference GlobeNewswire
Mar-19-20 08:30AM	Phathom Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Clinical Trial Status and Business Updates GlobeNewswire
Feb-25-20 04:35PM	Phathom Pharmaceuticals to Present at 40th Annual Cowen and Company Health Care Conference on March 2, 2020 GlobeNewswire
Jan-16-20 09:00AM	Frazier Healthcare Partners Closes Oversubscribed $617 Million Life Sciences Fund PR Newswire +5.16%
Jan-06-20 08:30AM	Phathom Pharmaceuticals Appoints Martin J. Gilligan as Chief Commercial Officer Business Wire +9.57%
Dec-23-19 08:30AM	Phathom Pharmaceuticals Announces Initiation of Pivotal Phase 3 Clinical Trial for Vonoprazan in Helicobacter Pylori (H. pylori) Infection Business Wire +15.59%
Dec-02-19 08:30AM	Phathom Pharmaceuticals Expands Leadership Team and Announces Board Transition Business Wire
08:30AM	Phathom Pharmaceuticals Announces Initiation of Pivotal Phase 3 Clinical Trial for Vonoprazan in Erosive Esophagitis Business Wire
Nov-26-19 08:30AM	Phathom Pharmaceuticals to Present at Evercore ISI 2019 HealthCONx Conference TEST Business Wire Releases
08:30AM	Phathom Pharmaceuticals to Present at Evercore ISI 2019 HealthCONx Conference Business Wire
Nov-25-19 08:30AM	Phathom Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update TEST Business Wire Releases
08:30AM	Phathom Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update Business Wire
Nov-13-19 04:05PM	Phathom Pharmaceuticals to Present at Jefferies 2019 London Healthcare Conference Business Wire
Oct-29-19 04:05PM	Phathom Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Oct-25-19 05:10PM	Phathom Pharmaceuticals Rises Almost 30% After $182 Million Bloomberg
Oct-24-19 08:25PM	Phathom Pharmaceuticals Announces Pricing of Initial Public Offering Business Wire

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is based in Buffalo Grove, Illinois.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nabulsi Azmi	Chief Operating Officer	Mar 02	Sale	45.90	9,127	418,928	794,700	Mar 03 08:20 PM
Nabulsi Azmi	Chief Operating Officer	Mar 01	Sale	45.85	5,373	246,362	803,827	Mar 03 08:20 PM
Socks David A	Director	Feb 23	Sale	43.74	4,984	217,991	1,435,945	Feb 23 06:14 PM
Socks David A	Director	Feb 22	Sale	45.66	20,140	919,587	1,440,929	Feb 23 06:14 PM
Socks David A	Director	Feb 19	Sale	47.18	44,876	2,117,034	1,461,069	Feb 23 06:14 PM
Nabulsi Azmi	Chief Operating Officer	Feb 02	Sale	40.97	9,084	372,156	809,200	Feb 03 04:05 PM
Nabulsi Azmi	Chief Operating Officer	Feb 01	Sale	38.09	5,416	206,285	818,284	Feb 03 04:05 PM
Socks David A	Director	Jan 12	Sale	36.07	27,165	979,795	1,532,945	Jan 13 05:07 PM
Socks David A	Director	Jan 11	Sale	34.92	12,835	448,243	1,560,110	Jan 13 05:07 PM
Socks David A	Director	Dec 17	Sale	40.74	48,212	1,964,376	1,572,945	Dec 18 08:01 PM
Socks David A	Director	Dec 16	Sale	47.53	31,446	1,494,519	1,621,157	Dec 18 08:01 PM
Nabulsi Azmi	Chief Operating Officer	Dec 02	Sale	45.26	7,302	330,512	838,200	Dec 03 06:01 PM
Nabulsi Azmi	Chief Operating Officer	Dec 01	Sale	44.20	7,198	318,176	845,502	Dec 03 06:01 PM
Socks David A	Director	Nov 11	Sale	38.97	6,877	268,021	1,652,603	Nov 12 04:13 PM
Socks David A	Director	Nov 10	Sale	41.69	12,681	528,672	1,659,480	Nov 12 04:13 PM
Socks David A	Director	Nov 09	Sale	42.33	10,784	456,506	1,676,562	Nov 12 04:13 PM
Nabulsi Azmi	Chief Operating Officer	Nov 02	Sale	36.83	14,500	534,026	852,700	Nov 03 06:40 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Apr 01	Buy	24.86	117,600	2,923,642	3,825,008	Apr 03 04:30 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Mar 31	Buy	24.55	30,600	751,264	3,707,408	Mar 31 05:02 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Mar 27	Buy	24.60	30,000	738,000	3,676,808	Mar 31 05:02 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience